Drug Profile
Research programme: small molecule therapeutics - Syros Pharmaceuticals
Alternative Names: CDK 11 inhibitors; CDK12 inhibitor; CDK12/12 inhibitors - Syros Pharmaceuticals; Cyclin-dependent kinase 12/13 inhibitors - Syros Pharmaceuticals; SY 351; SY-12882; THZ1; THZ531; WRN inhibitorsLatest Information Update: 21 Aug 2023
Price :
$50
*
At a glance
- Originator Syros Pharmaceuticals
- Developer Dana-Farber Cancer Institute; Syros Pharmaceuticals; Whitehead Institute for Biomedical Research
- Class Antianaemics; Antidementias; Antineoplastics; Small molecules; Urologics
- Mechanism of Action Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; Gene expression modulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Alzheimer's disease; Autoimmune disorders; Cancer; Ewing's sarcoma; Neuroblastoma; Ovarian cancer; Polycystic kidney disease; Precursor cell lymphoblastic leukaemia-lymphoma; Sickle cell anaemia; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 02 Jun 2023 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 26 Oct 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)